• Poly(I:C) and JPH2: A dsRNA Sensing Checkpoint

  2026-10-16

  The 2024 JPH2 study supports a model in which junctophilin-2 binds double-stranded RNA and restrains MDA5-dependent innate immune signaling in cardiomyocytes. Poly(I:C) was used as a synthetic dsRNA mimic in the study’s binding and sensing assays, but the findings do not establish the performance of any supplier-specific formulation or validate broader catalog claims about dendritic-cell maturation or hPSC-derived cardiomyocytes.

• GI 254023X: What the Product Record Supports

  2026-10-15

  GI 254023X is described by APExBIO as a selective ADAM10 inhibitor with reported activity in biochemical, cellular, endothelial, and mouse toxin-injury contexts. Because no identity-matched research paper is available here, the compound’s mechanism, selectivity, and protective effects should be treated as supplier-reported claims rather than independently verified findings.

• JPH2 as a Brake on Cardiomyocyte dsRNA Sensing

  2026-10-15

  A literature-focused analysis of a 2024 study identifying junctophilin-2 as a cardiomyocyte dsRNA-binding protein that may restrain MDA5-dependent innate immune signaling. The article separates the study’s evidence from supplier claims about Poly(I:C), a synthetic double-stranded RNA analog, and discusses mechanism, comparators, limitations, and applicability boundaries.

• Poly(I:C), JPH2, and dsRNA Sensing in Cardiomyocytes

  2026-10-14

  Evidence from cardiomyocyte and mouse models identifies junctophilin-2 as a dsRNA-binding regulator that may restrain MDA5-dependent innate immune signaling. Poly(I:C) was used in the study as a synthetic dsRNA mimic and binding probe, but the findings do not establish that a particular commercial formulation, supplier, or TLR3 pathway caused the reported cardiomyocyte responses. The strongest conclusion is mechanistic: JPH2 can associate with dsRNA and its loss is associated with increased MDA5–MAVS–TBK1 signaling and interferon-beta production.

• Poly(I:C): Evidence, Scope and Limits

  2026-10-14

  Poly(I:C) is a synthetic double-stranded RNA analog used conceptually to model selected innate immune signals, especially interferon-associated responses. Available supplied evidence supports its identity and intended research scope, but does not establish universal effects across cell types or validate claims about dendritic-cell or cardiomyocyte maturation. A separate macrophage study on LPS, TLR4/TRIF and endogenous melatonin offers mechanistic context—not direct evidence for Poly(I:C).

• Poly(I:C) and Cardiac dsRNA Sensing

  2026-10-13

  Poly(I:C) is a synthetic double-stranded RNA analog commonly described as a TLR3 agonist and interferon inducer. Recent work on junctophilin-2 (JPH2) adds important context: cardiomyocytes may regulate dsRNA sensing through sequestration of RNA away from the cytosolic sensor MDA5. However, that study does not directly establish how Poly(I:C) behaves in cardiomyocytes, nor does it validate product-specific claims about dendritic-cell or hPSC-derived cardiomyocyte maturation.

• HEPES and the Limits of Rabbit Pharming Evidence

  2026-10-13

  HEPES is a physiological pH buffer used in cell culture and biochemical assays, whereas Song et al. report a separate proof of concept for targeted, heritable rabbit milk expression. The reported 15–20 g/L tdTomato concentration does not establish a role for HEPES, intracellular pH modulation, or lysosomal biogenesis support, nor does it demonstrate equivalent performance for therapeutic proteins.

• Poly(I:C) and Liver Disease: Evidence Boundaries

  2026-10-12

  The supplied evidence supports a conceptual link between innate immune signaling, hepatocyte death, and liver-disease progression, but it does not establish Poly(I:C) as a hepatic treatment or validate product-specific outcomes. The central limitation is provenance: the cited source is a broad review of liver-cell death, whereas Poly(I:C)-specific claims come only from supplier information.

• Cy3 Detection and HMGB1 Biomarker Evidence

  2026-10-12

  This overview separates supplier-described fluorescence detection from the iScience evidence identifying HMGB1 as a candidate diabetic-nephropathy biomarker, with emphasis on evidence strength, interpretation, and applicability boundaries.

• Super-Enhancer RNA and NPC Metastasis: Study Overview

  2026-10-11

  A source-grounded overview of a 2023 study linking carcinogen-associated exposure to nasopharyngeal carcinoma metastasis through seRNA-NPCm, NPM1/c-Myc, and NDRG1, with attention to evidence strength, provenance, and applicability limits.

• Cardiac Biomarkers in Epileptic Baboons

  2026-10-10

  A retrospective study in a pedigreed captive baboon population identified prolonged QT and QTcF intervals in epileptic animals, with a nonsignificant reduction in RMSSD-based heart rate variability. The work strengthens the baboon as a translational model for epilepsy-related cardiac abnormalities and SUDEP research, while its retrospective design and limited ECG sampling constrain causal and predictive conclusions.

• Lowe Syndrome iPSC Models: CRISPR and OCRL Rescue

  2026-10-09

  This Advanced Science study establishes patient-derived trabecular meshwork models for investigating Lowe syndrome-associated glaucoma and compares two complementary therapeutic concepts: mutation-agnostic OCRL DNA augmentation and patient-specific CRISPR-mediated correction. The findings link restored OCRL activity and cellular rescue to extracellular matrix, adhesion, and cytoskeletal pathways, while remaining preclinical and model-limited.

• Mubritinib-Inspired HER2–EMT Breast Cancer Study

  2026-10-09

  A 2022 European Journal of Medicinal Chemistry study used a Mubritinib-derived scaffold to create 32 candidate HER2 inhibitors and identified Q7j as the leading compound. The findings connect HER2 phosphorylation with migration-related EMT changes in SKBR3 breast cancer models, while also showing why the evidence remains preclinical and model-dependent.

• GANT61 and GLI Biology in Cancer Research

  2026-10-08

  A source-grounded overview of GANT61 as a GLI-focused research tool, with emphasis on Hedgehog pathway biology, the GLI2–PRDX1 ferroptosis axis in bladder cancer, evidence comparison, and translational limitations.

• AT-406 (SM-406): IAP Antagonist Evidence

  2026-10-08

  AT-406, also called SM-406, is a research-stage antagonist of XIAP, cIAP1, and cIAP2. Product-dossier evidence supports apoptosis-related activity in cancer models, but assay metadata, independent replication, and clinical evidence remain limited.

553 records 1/37 page Next 12345 下5页 Last page